Resistance to AKT/mTOR inhibitors, triciribidine, and everolimus occurred in B7-H3 overexpressed breast cancer cell lines, and knockdown of B7-H3 reversed the resistance to these drugs via decreasing the glycolytic capacity [67]. The gene discussed is CD276; the disease is breast carcinoma.